Obviohealth Unveils Obviogo, A Next-Generation DCT Platform, And Mobile Application

ObvioGo's adaptive technology stack captures and integrates more precise multi-source data, enabling a unified platform for clinical research teams to deliver more robust therapeutic evidence.

FREMONT, CA: "What I find so exciting about ObvioGo is the innovative ways in which we've combined cloud-native and AI-enriched platform technologies with clinical science expertise and digital best practices. Our machine learning technologies remove repetitive tasks while providing deeper insights. By automating low-value processes, we are enabling humans—both patients and clinicians—to focus on the added value efforts that deliver stronger outcomes." says Craig Gravina, ObvioHealth's Chief Technology Officer.

ObvioHealth, one of the pioneering virtual research organizations (VRO), announces the debut of ObvioGo, a decentralized clinical trial platform and mobile application designed to give more substantial proof of therapeutic efficacy and safety.

While the pandemic has hastened the implementation of remote technologies to decrease patient burden, current DCT providers have not yet taken the opportunity to collect clinical outcomes that are less biased and more trustworthy.